Dramatic responses to the BRAF inhibitor, vemurafenib, and preclinical as well as early clinical reports of enhanced antigen expression and a favorable tumor microenvironment in patients treated with such targeted agents led to our attempt to combine this agent in BRAF-mutated melanoma [19–25]. The gene discussed is BRAF; the disease is neoplasm.